We are proud to be nationally ranked for the 13th year in a row for Product Liability, Mass Tort and Class Action – Defense: Pharmaceuticals and Medical Devices by The Legal 500. The Legal 500 notes, “As one of the core industry groups within litigation boutique Bowman and Brooke LLP’s acclaimed product liability defense offering, pharmaceutical and medical devices work accounts for a significant volume of work for lawyers throughout its national network of offices. The firm’s roles run the gamut from regional and local counsel, through to trial and national coordinating positions, with a collaborative style of working that is a great advantage on large-scale cases involving co-counsels and co-defendants.” Executive Managing Partner Kim M. Schmid (Minneapolis) and Partner Randall Christian (Austin) are named as Leading Lawyers. Kim and Randy serve as co-chairs of the firm's Medical Device and Pharmaceutical Practice Group. Other Key Lawyers recognized are Managing Partner Chris Carton (New Brunswick and New York), Managing Partner John Garrett (Austin) and Co-Managing Partner Erica Singer Mekles (New Brunswick and New York). Read more about Bowman and Brooke’s 2024 The Legal 500 rankings: https://bit.ly/3W5Ssiv #Legal500 #Pharmaceutical #MedicalDevice #Pharma #LifeSciences #Law #LawFirm
Bowman and Brooke’s Post
More Relevant Posts
-
#Litigation attorney Eric Alexander authored an article featured in Drug & Device Law analyzing #liability theories on decisions to continue or halt sales of #prescriptiondrugs, using the #Fabrazyme shortage litigation as a case study. He critiques the merits of “stop selling” and “keep selling” claims, questioning whether #plaintiffs’ evolving allegations over time should allow cases to proceed. His analysis offers a strong skepticism of these emerging liability theories against #pharmaceutical companies. Click here to read and learn more. #productliability
To view or add a comment, sign in
-
Attention to all legal professionals and law firms! 📢 With the Ozempic weight loss MDL looming, law firms have a unique opportunity to make a real impact. By proactively purchasing leads, you position your firm at the forefront of this evolving legal landscape. 💼⚖️ Don't wait for the competition to seize the opportunity—take action now to secure your firm's success. Ozempic has been hailed as a breakthrough in weight loss treatment, but it's not without its controversies. If your firm specializes in representing individuals affected by pharmaceutical issues, our Ozempic web leads are the solution you've been searching for. Ready to elevate your practice with Ozempic web leads? Don't miss out on this opportunity to expand your client base and make a meaningful impact in pharmaceutical litigation. Contact us today to learn more about our Ozempic web leads and how they can benefit your firm. Let's work together to achieve justice for those affected by pharmaceutical issues. Call s at (202) 773-9477 Email us at [email protected] www.rainmaker-legal.com #Ozempic #WebLeads #PharmaceuticalLitigation #LawFirms #rainmakerlegalleads #LegalServices⁶
To view or add a comment, sign in
-
-
In a significant legal development, MSP Recovery Law Firm LLC, representing LifeWallet, has secured a $3.1 million settlement in an antitrust case involving a pharmaceutical manufacturer. The case, which alleged that the drug maker had unlawfully increased the price of a medication in violation of antitrust laws, marks a notable victory for LifeWallet’s ongoing efforts to hold healthcare entities accountable for unfair practices... #antitrust #antitrustlaw #competitionlaw #pharmaceutical
LifeWallet Reaches $3.1 Million Settlement in Antitrust Case Against Drug Manufacturer
https://www.pymnts.com
To view or add a comment, sign in
-
Some kind words from one of our partners, Doug Snyder, the former Chief Legal Officer at GW Pharmaceuticals, Actelion, and Eisai. "As the former Chief Legal Officer at Eisai, Actelion, and GW Pharmaceuticals, I have had the pleasure of working with Lovell since their inception in 2010. Their team of attorneys with diverse practice areas offers exceptional and creative contract support that is both friendly and knowledgeable. Lovell’s cost-effective approach to everyday contract needs is unparalleled, making them an indispensable partner for global pharmaceutical companies. I wholeheartedly recommend Lovell for their extraordinary work." Team up with us at LovellLawGroup.com #corporatelawfirm #lawfirm #contracts #contractspecialists #contractsupport #contractmanagement #outsourcedcontracts #lifescience #lifesciencecontract #industryneutral #industryneutralcontract #legalservices #legal #inhouse #attorneys #contractprocess #contractingprocess #lovell
To view or add a comment, sign in
-
-
📢 This week's Patexia Insight 📊 In our latest article, we dive deep into ANDA (Abbreviated New Drug Application) litigation, unveiling the top-performing brand and generic companies. Discover the evolving trends in the pharmaceutical industry's legal landscape. Read more ➡️ https://lnkd.in/dRUpYUEA The full ANDA Litigation Intelligence Report offers a comprehensive analysis of ANDA-related data spanning a 5-year period, from July 1, 2018, to June 30, 2023. This in-depth examination encompasses 1,428 ANDA cases, 1,774 patents, 1,936 attorneys, 226 law firms, 469 pharmaceutical companies, and interactions within the legal landscape involving 153 judges. Moreover, this report includes insights and analysis on the trends that shape the pharmaceutical industry's legal landscape such as the outcome analysis, most frequently encountered IPC codes, top ANDA jurisdictions, and more. Get your copy of the report here ➡️ https://lnkd.in/dEhuTyuM #Pharmaceuticals #ANDA #Litigation #Legal #pharma #generic #drugs
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
services.patexia.com
To view or add a comment, sign in
-
📢 Latest Patexia Insight 📊 In our latest article, we dive deep into ANDA (Abbreviated New Drug Application) litigation, unveiling the top-performing brand and generic companies. Discover the evolving trends in the pharmaceutical industry's legal landscape. Read more ➡️ https://lnkd.in/dtj_gc3s The full ANDA Litigation Intelligence Report offers a comprehensive analysis of ANDA-related data spanning a 5-year period, from July 1, 2018, to June 30, 2023. This in-depth examination encompasses 1,428 ANDA cases, 1,774 patents, 1,936 attorneys, 226 law firms, 469 pharmaceutical companies, and interactions within the legal landscape involving 153 judges. Moreover, this report includes insights and analysis on the trends that shape the pharmaceutical industry's legal landscape such as the outcome analysis, most frequently encountered IPC codes, top ANDA jurisdictions, and more. Get your copy of the report here ➡️ https://lnkd.in/dsUR_-a8 #Pharmaceuticals #ANDA #Litigation #Legal #pharma #generic #drugs
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
services.patexia.com
To view or add a comment, sign in
-
Drew W. Broaddus, Partner, Troy, authored a Product Liability Newsline article, “Michigan Drug Immunity Repeal Gives Shot in the Arm to Plaintiffs’ Bar.” > https://bit.ly/3GA8HvM Since 1995, pharmaceutical manufacturers and sellers have enjoyed tort immunity in Michigan under MCL 600.2946 when (1) the drug was approved by the federal Food and Drug Administration (“FDA”), (2) the manufacturer or seller did not fraudulently obtain the approval, (3) the drug and its labeling complied with the approval, and (4) the approval was not withdrawn. According to Senate Bill Analysis, this statute was generally recognized as the strongest such immunity protection in the United States. Indeed, as of 2023, Michigan was the only state that statutorily offered drug manufacturers a blanket defense for products liability. This week, Governor Gretchen Whitmer (D) signed Senate Bill (“SB”) 410, repealing this immunity. Info re: Mr. Broaddus > https://bit.ly/3PDHaPn contact [email protected] or 616-272-7966; sign up for Secrest Wardle newsletters > https://bit.ly/3PtRmKg #secrestwardle #law #legalnewsletter #productliability #insurancedefense
To view or add a comment, sign in
-
-
📢 Latest Patexia Insight 📊 In our latest article, we dive deep into ANDA (Abbreviated New Drug Application) litigation, unveiling the top-performing brand and generic companies. Discover the evolving trends in the pharmaceutical industry's legal landscape. Read more ➡️ https://lnkd.in/dtj_gc3s The full ANDA Litigation Intelligence Report offers a comprehensive analysis of ANDA-related data spanning a 5-year period, from July 1, 2018, to June 30, 2023. This in-depth examination encompasses 1,428 ANDA cases, 1,774 patents, 1,936 attorneys, 226 law firms, 469 pharmaceutical companies, and interactions within the legal landscape involving 153 judges. Moreover, this report includes insights and analysis on the trends that shape the pharmaceutical industry's legal landscape such as the outcome analysis, most frequently encountered IPC codes, top ANDA jurisdictions, and more. Get your copy of the report here ➡️ https://lnkd.in/dsUR_-a8 #Pharmaceuticals #ANDA #Litigation #Legal #pharma #generic #drugs
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
services.patexia.com
To view or add a comment, sign in
-
Generative AI, clinical trial agreement templates and the benefits of negotiating to uphold liability clauses! Find out more in this week's edition of our #Pharmaceutical & #LifeSciences law brief: https://bit.ly/495Xmzw Stay up to date and subscribe to our law briefs now: https://bit.ly/41M4L4I
To view or add a comment, sign in
-
This update affects businesses such as consulting firms, law firms, pharmaceutical firms, real estate businesses, medical companies and any other profession that requires specialized knowledge and skills. If you are planning to register a business that falls under this category, make sure to obtain a proficiency certificate before proceeding to register with the Corporate Affairs Commission. For advice and support for seamless registration, send us a DM or talk to Grace on 0903 408 6536 #Kudination #CACRegistration #NigeriaEntrepreneurs #update
To view or add a comment, sign in
Partner at Bowman and Brooke LLP
2moSo proud of my colleagues.